Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $4.5052W HIGH $11.45
Volume
236.68 K
Value Traded
16.81 M
Short % Float
15.65%
-2.63%Week
-18.05%1 Month
+20.76%3 Month
+67.92%6 Month
-54.26%5 Year
-54.26%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
547.85 M
EPS (TTM)
-0.76
P/E Ratio
-
Ent. Value
293.06 M
Total Shares
61.59 M
Float Shares
65.58 M
Insiders
7.52%
Institutions
70.08%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
SGMT Catalyst Timeline
Dated clinical, regulatory and corporate events for Sagimet Biosciences Inc. - Series A
Catalyst Timeline
Dated clinical, regulatory & corporate events for Sagimet Biosciences Inc. - Series A
168Total events
16Upcoming
48Tier-1 (high impact)
2022 to 2028Coverage
Upcoming catalysts 2
Event history 50
▼Equity OfferingCorporate
Closing of underwritten offering of Series A common stock and pre-funded warrants for ~$115.0M gross proceeds
●R&D DayDenifanstatFiledPresentation
Sagimet to host virtual KOL event on denifanstat 52-week OLE data and planned AURORA Phase 3 trial
moderate to severe acne vulgarissource ↗
▲Full ResultsDenifanstatFiledClinical Data
Positive full 52-week results from Phase 3 OLE trial of denifanstat in acne presented at EADV 2026
moderate to severe acne vulgarissource ↗
▲Oral PresentationDenifanstatFiledPresentation
52-week OLE results of denifanstat in acne presented at EADV 2026 in Vienna
moderate to severe acne vulgarissource ↗
●R&D DayPresentation
Sagimet to host virtual KOL event and webcast on 52-week denifanstat data and AURORA update
moderate to severe acne vulgarissource ↗
▼Equity OfferingCorporate
Pricing of $115.0M underwritten offering of Series A common stock and pre-funded warrants
▲Long Term DataDenifanstatFiledClinical Data
52-week data from Ascletis' Phase 3 open-label extension of denifanstat in China showed improvements in all efficacy endpoints
moderate to severe acne vulgarissource ↗
▲Oral PresentationDenifanstatFiledPresentation
52-week denifanstat OLE efficacy results to be presented at EADV 2026
moderate to severe acne vulgarissource ↗
▲IND ClearanceDenifanstatFiledIND
FDA cleared IND and issued Study May Proceed letter for Phase 3 trial of denifanstat in acne
moderate to severe acnesource ↗
▼Equity OfferingCorporate
Inducement grant of 34,300 stock options to two new employees under Nasdaq Rule 5635(c)(4)
●IND SubmissionDenifanstatFiledIND
IND submission for denifanstat in moderate to severe acne
moderate to severe acnesource ↗
▲Poster PresentationDenifanstatFiledPresentation
Poster presentation at EASL 2026: Transcriptomic analysis of FASN inhibitor and resmetirom combination in LDL receptor knockout MASH mice
MASHsource ↗
▲Poster PresentationDenifanstatFiledPresentation
Poster presentation at EASL 2026: Denifanstat and resmetirom combination therapy rapidly decreased atherogenic lipids in healthy adults in Phase 1 open-label trial (Best of EASL)
MASHsource ↗
◆Poster PresentationPresentation
Poster presentation at SID 2026 on FASN inhibitors reducing sebum lipids in human sebocytes
acnesource ↗
▼Equity OfferingCorporate
Pricing of $175.0 million underwritten offering of Series A common stock at $6.00 per share
◆Oral PresentationDenifanstatFiledPresentation
Oral presentation: Reduction of plasma glycine- and taurine-conjugated bile acids correlated with histological improvements in denifanstat-treated MASH patients in Phase 2b FASCINATE-2 trial
MASHsource ↗
◆Poster PresentationDenifanstatFiledPresentation
Poster presentation: Reduction of plasma glycine- and taurine-conjugated bile acids correlated with histological improvements in denifanstat-treated MASH patients in Phase 2b FASCINATE-2 trial
MASHsource ↗
▼Equity OfferingCorporate
Inducement grant of 9,600 stock options to newly hired employee under Nasdaq Rule 5635(c)(4)
◆Trial InitiationDenifanstatFiledTrial
Phase 3 trial of denifanstat in acne to initiate in 2H 2026
moderate to severe acnesource ↗
◆Trial InitiationDenifanstatFiledTrial
Phase 2 trial of denifanstat + resmetirom for F4 MASH estimated to start in 2H 2026
MASH (F4 cirrhosis)source ↗
●Oral PresentationDenifanstatFiledPresentation
Presentation of bile acid biomarker analyses from FASCINATE-2 at Keystone Symposium
MASHsource ↗
●Management ChangeCorporate
Appointment of Andreas Grauer as CMO and retirement of former CMO
▲Topline ReadoutDenifanstatFiledClinical Data
Topline results from Ascletis' Phase 3 denifanstat trial in China announced
moderate to severe acne vulgarissource ↗
▲Topline ReadoutDenifanstatFiledClinical Data
Positive topline results from Phase III open-label study of denifanstat (ASC40) in acne
moderate-to-severe acne vulgarissource ↗
◆NMPA NDA ApprovalDenifanstatFiledEx-US Regulatory
NDA for denifanstat (ASC40) for acne accepted by China NMPA
acnesource ↗
▲Topline ReadoutDenifanstatFiledClinical Data
Positive topline results from open-label Phase 3 long-term safety trial of ASC40 in moderate to severe acne
moderate to severe acnesource ↗
◆Topline ReadoutDenifanstatFiledClinical Data
Data readout from Phase 1 PK trial of denifanstat + resmetirom expected in 1H 2026
MASHsource ↗
▲Trial CompletionDenifanstatFiledTrial
Completed Phase 1 PK clinical trial of denifanstat and resmetirom combination
MASHsource ↗
▲Topline ReadoutDenifanstatFiledClinical Data
Positive topline results in open-label Phase 3 acne trial in China reported by Ascletis
moderate to severe acnesource ↗
▲NDA SubmissionDenifanstatFiledRegulatory Filing
NMPA accepted Ascletis' NDA for denifanstat for moderate to severe acne
moderate to severe acnesource ↗
▲Partnership / LicenseCorporate
Secured global, exclusive license to TAPI's innovative forms of resmetirom active pharmaceutical ingredient
▲Partnership / LicenseCorporate
Global license agreement with TAPI for innovative forms of resmetirom API for FDC program
▲NMPA NDA ApprovalDenifanstatFiledEx-US Regulatory
NMPA accepted NDA for denifanstat for moderate to severe acne
moderate to severe acnesource ↗
▲Topline ReadoutDenifanstatFiledClinical Data
Topline safety data reported in December 2025 for denifanstat/resmetirom combination Phase 1 trial
MASHsource ↗
●Trial CompletionDenifanstatFiledTrial
Phase 1 PK clinical trial of denifanstat and resmetirom combination completed
MASHsource ↗
▲NDA SubmissionDenifanstatFiledRegulatory Filing
NDA accepted by NMPA for denifanstat in acne
acne vulgarissource ↗
◆Topline ReadoutDenifanstatFiledClinical Data
Topline data from Phase 1 PK trial anticipated by end of 2025
MASHsource ↗
▲FDA Filing AcceptedDenifanstatFiledRegulatory Filing
NDA for denifanstat in acne accepted by NMPA
acnesource ↗
▲Trial InitiationDenifanstatFiledTrial
Phase 1 PK trial of denifanstat + resmetirom initiated
MASH cirrhosis (F4 fibrosis)source ↗
●Timing GuidanceDenifanstatFiledPresentation
Ascletis plans to submit NDA to NMPA for denifanstat in acne
moderate-to-severe acne vulgarissource ↗
▲Poster PresentationDenifanstatFiledPresentation
Poster presentation at AASLD 2025: Denifanstat improved fibrosis, inflammation and steatosis in advanced qF4 MASH patients
MASHsource ↗
Past FDA Catalysts and PDUFA Decisions
How SGMT actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-09-30 | denifanstat | Phase 3 data presentation | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C53 / 100
Pipeline Score
$491M
Pipeline Value
Fair Value
Valuation Signal
4
Drugs Scored
0.9x
rNPV / MCap
Top 14%
Micro Cap(rank 93 of 658)
Percentile Rank
Sagimet Biosciences Inc. - Series A carries a moderate pipeline score (53/100), with $1.2B risk-adjusted pipeline value, led by TVB-2640 in Solid Malignant Tumor (Phase 1).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| TVB-2640 Small moleculeCompletedNCT04906421 | Metabolic Dysfunction-assocated Steatohepatitis/ Nonalcoholic Fatty Liver Disease | Phase 2 | COMPLETED | 168 | Oct 2, 2023 |
Clinical Trial Results
Readouts, endpoints and source filings for every SGMT program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| denifanstat Breakthrough | moderate to severe acne vulgaris | Phase 3 | 2026-10-09 | 57% IGA success; 72% reduction in total lesions; 77% reduction in inflammatory lesionsRead More | Sagimet To Present Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne and Mechanistic Data at the 2026 Fall Clinical Dermatology ConferenceRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Kemble GeorgeDirector | Option | 326,618 388,779 held | $6.36 | 08/14/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in SGMT
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| SILVERARC CAPITAL MANAGEMENT, LLC | 2.4 % (2,300 %) | 22.63 M | 2.93 M | 7,699.08% ( 2.89 M) |
SGMT Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2028-07-21 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How SGMT ranks across every disease it competes in
Competitive Position is a premium feature
See how SGMT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialSGMT News
SGMT▼ -0.2%today
Sagimet To Present Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne and Mechanistic Data at the 2026 Fall Clinical Dermatology Conference
Sagimet Biosciences announced positive results from the Phase 3 ASC40-304 trial of denifanstat for moderate to severe acne, showing sustained efficacy over 52 weeks. The drug demonstrated a 57% success rate in Investigator's Global Assessment and significant reductions in lesion counts. The findings will be presented at the 2026 Fall Clinical Dermatology Conference, highlighting the potential of FASN inhibition in acne treatment.
Read more →SGMTSagimet Biosciences Announces Closing of Underwritten Offering of Series A Common Stock and Pre-Funded Warrants
Sagimet Biosciences has successfully closed an underwritten offering of 8,750,010 shares of Series A common stock, raising about $115 million. The proceeds will be used to fund a Phase 3 clinical trial for denifanstat, along with other corporate purposes. The offering was led by Commodore Capital, with participation from various institutional investors.
Read more →SGMT▲ +5.9%on this newsshared move
Sagimet Biosciences Announces Pricing of $115.0 Million Underwritten Offering of Series A Common Stock and Pre-Funded Warrants
Sagimet Biosciences has announced the pricing of an underwritten offering of $115 million, selling shares of its Series A common stock and pre-funded warrants. The proceeds will be used to fund a Phase 3 clinical trial for denifanstat, among other corporate purposes. The offering is expected to close on October 1, 2026, pending customary conditions.
Read more →SGMT▲ +5.9%on this newsshared move
Sagimet Announces Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne Presented at EADV 2026
Sagimet Biosciences announced positive results from the Phase 3 open-label extension trial of denifanstat for moderate to severe acne, showing sustained efficacy and safety over 52 weeks. The drug achieved a 57% success rate in the Investigator's Global Assessment and significant reductions in skin lesions. Patient screening for the U.S. AURORA Phase 3 trial is set to begin in October 2026.
Read more →SGMT▲ +7.6%on this newsshared move
Sagimet Biosciences to Host Virtual KOL Event, “Denifanstat Update: 52-Week Data from Phase 3 Open-Label Extension in China and Planned AURORA Phase 3 Clinical Trial in US” on September 30, 2026
Sagimet Biosciences will host a virtual KOL event on September 30, 2026, to discuss the 52-week data from the Phase 3 open-label extension trial of denifanstat for moderate to severe acne. The event will feature Dr. Julie Harper and will cover the drug's efficacy and the upcoming AURORA Phase 3 trial in the U.S. Denifanstat has shown promising results in previous trials and is expected to enter a new phase of clinical testing soon.
Read more →SGMTSagimet Biosciences Announces Participation in Two Upcoming Investor Conferences
Sagimet Biosciences Inc. has announced its participation in two upcoming investor conferences in New York. The Cantor 2026 Global Healthcare Conference will feature a fireside chat on September 9, 2026, while the H.C. Wainwright 28th Annual Global Investment Conference is scheduled for September 14, 2026. These events highlight Sagimet's ongoing efforts to engage with the investment community.
Read more →SGMTSagimet Biosciences Advances AURORA U.S. Phase 3 Trial of Denifanstat in Acne Toward Patient Enrollment in Q4 2026
Sagimet Biosciences announced that its AURORA Phase 3 clinical trial for denifanstat in moderate to severe acne is set to begin patient enrollment in Q4 2026. The trial will involve around 800 patients, including adolescents, and will assess the efficacy and safety of denifanstat, which could be the first new oral acne treatment in decades. The company is prepared for patient screening and anticipates submitting an NDA after the trial's completion.
Read more →SGMTSagimet Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Sagimet Biosciences has announced an inducement grant of 260,700 stock options to three newly hired employees. This grant, approved by the Compensation Committee, is part of the employment compensation and aims to attract talent under Nasdaq Rule 5635(c)(4). The options have a ten-year term and vest over four years.
Read more →SGMTSagimet Biosciences Receives FDA “Study May Proceed” Letter and IND Clearance for Phase 3 Trial in Acne in Adolescent and Adult Patients
Sagimet Biosciences has received FDA clearance for its Phase 3 clinical trial of denifanstat, a fatty acid synthase inhibitor, aimed at treating moderate to severe acne. The trial will enroll approximately 800 patients, including 450 adolescents, and is set to begin in the second half of 2026. This marks a crucial step in the development of denifanstat, which has shown promising results in earlier trials.
Read more →SGMTSagimet Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
Sagimet Biosciences has reported its financial results for the second quarter of 2026, highlighting the progress of its clinical trials. The Phase 3 trial for denifanstat, aimed at treating moderate to severe acne, is set to start in the second half of 2026. Additionally, the first-in-human Phase 1 trial for the FASN inhibitor TVB-3567 is currently ongoing, and the company secured $175 million in equity financing.
Read more →SGMT▲ +11.7%on this news· ran to +27% by day 3
Sagimet Biosciences to Participate in the Canaccord Genuity 46th Annual Growth Conference
Sagimet Biosciences Inc. will participate in the Canaccord Genuity 46th Annual Growth Conference on August 11, 2026, in Boston, MA. The company is known for developing novel FASN inhibitors targeting metabolic and fibrotic pathways. This participation highlights Sagimet's commitment to engaging with investors and showcasing its innovative therapeutic developments.
Read more →SGMT▲ +10.3%on this news
Sagimet Biosciences Joins the Russell 2000® and Russell 3000® Indexes
Sagimet Biosciences has been added to the Russell 2000 and 3000 indexes, effective immediately. This inclusion reflects the company's progress and is expected to enhance its visibility in the market. Sagimet plans to initiate a Phase 3 clinical trial for denifanstat, targeting moderate to severe acne, later this year. If successful, denifanstat could be the first new oral treatment for acne in over forty years.
Read more →SGMTSagimet Biosciences Announces Participation in Upcoming Investor Conference and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Sagimet Biosciences has announced its participation in the upcoming Leerink Partners Therapeutics Forum in Boston on July 15, 2026. Additionally, the company approved an inducement grant of 34,300 stock options to two newly hired employees as part of their compensation. This grant aligns with Nasdaq Rule 5635(c)(4) and aims to attract talent to support Sagimet's development of novel therapeutics targeting metabolic and fibrotic pathways.
Read more →SGMTSagimet Biosciences Presents Two Posters at EASL 2026 on Denifanstat/Resmetirom Combination in MASH
Sagimet Biosciences presented two posters at EASL 2026, showcasing Phase 1 clinical data on the combination of denifanstat and resmetirom. The combination therapy demonstrated rapid reductions in cholesterol levels and was generally well-tolerated. This research highlights the potential cardiovascular benefits and therapeutic efficacy for MASH and liver fibrosis.
Read more →SGMTSagimet Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
Sagimet Biosciences will participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, 2026. The event will feature a fireside chat with management, showcasing their novel therapeutics targeting metabolic and fibrotic pathways. A webcast of the chat will be available on their website.
Read more →SGMTSagimet Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates
Sagimet Biosciences reported its financial results for Q1 2026, highlighting a successful $175 million equity financing. The company plans to initiate a Phase 3 clinical trial of denifanstat for moderate to severe acne in the U.S. in the second half of 2026. Additionally, a Phase 1 trial of the FASN inhibitor TVB-3567 is ongoing, with expectations to fund operations through 2028.
Read more →SGMTSagimet Biosciences to Present Mechanism of Action Data for its FASN Inhibitors at the Society for Investigative Dermatology in Chicago
Sagimet Biosciences announced it will present data at the Society for Investigative Dermatology Annual Meeting, showcasing the potential of FASN inhibitors in treating acne. The pre-clinical studies indicated that these inhibitors reduce sebum production, a key factor in acne development. A Phase 3 clinical trial for denifanstat is set to begin in late 2026.
Read more →SGMT▲ +38.6%on this news· ran to +49% by day 1
Sagimet Biosciences Announces Pricing of $175.0 Million Underwritten Offering of Series A Common Stock
Sagimet Biosciences has announced the pricing of an underwritten offering of 29.17 million shares of its Series A common stock at $6.00 per share, aiming to raise approximately $175 million. The proceeds will primarily fund a Phase 3 clinical trial for denifanstat in acne and support other clinical developments. The offering is set to close on or about April 28, 2026.
Read more →SGMT▲ +38.6%on this news· ran to +49% by day 1shared move
Sagimet Biosciences Provides Strategic and Corporate Updates
Sagimet Biosciences announced plans to initiate a Phase 3 clinical trial of denifanstat for moderate to severe acne in the U.S. in late 2026, following positive results from a trial in China. The company is also conducting a Phase 1 trial for another FASN inhibitor, TVB-3567. Development for MASH will be paused until non-dilutive funding is secured. Sagimet will host a KOL event on April 30, 2026, to discuss its acne treatment plans.
Read more →SGMT▲ +38.6%on this news· ran to +49% by day 1shared move
Targeting MetabolicDysfunction with Novel Therapeutics April 2026 April 2026 2 Forward-Looking Statements and Disclaimer This presentation contains forward-looking statements within the meaning of, and made pursuant to t
Sagimet Pharma is advancing its clinical programs for two promising therapeutics: TVB-3567 and denifanstat. TVB-3567 is currently in a Phase 1 trial for moderate to severe acne, with plans for a Phase 2 trial anticipated in 2026. Denifanstat has shown positive results in Phase 2b trials for metabolic dysfunction-associated steatohepatitis (MASH) and a significant combination therapy with resmetirom is in development. Safety and efficacy of denifanstat were well-demonstrated across clinical trials, prompting the company to explore further study in MASH and acne.
Read more →About Sagimet Biosciences Inc. - Series A
Headquarters950 TOWER LANE, FOSTER CITY, CA, 94404
BIOPHARMAWATCH ELITE PLUS
Trade the next SGMT catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime